Document Detail


Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment.
MedLine Citation:
PMID:  23421567     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background: Interactions between human immuno-deficiency virus (HIV) and opioid-dependence therapies can occur. Objectives: We sought to determine whether such interactions occurred between buprenorphine/naloxone and raltegravir. Methods: We performed a within-subject open-labeled pharmacokinetic and pharmacodynamic study in 12 HIV-seronegative subjects stabilized on at least 3 weeks of buprenorphine/naloxone therapy. Subjects underwent baseline and steady-state evaluation of the effect of raltegravir 400 mg BID on buprenorphine/naloxone parameters. Results: Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir. Similar analyses of norbuprenorphine, the primary metabolite of buprenorphine, demonstrated no significant difference after raltegravir administration. Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h). Objective opioid withdrawal was not observed. The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively. Conclusion: The addition of raltegravir to stabilized patients receiving buprenorphine/naloxone does not significantly affect buprenorphine/naloxone or raltegravir pharmacokinetic or pharmacodynamic parameters.
Authors:
R Douglas Bruce; David E Moody; Diane Chodkowski; Laurie Andrews; Wenfang B Fang; Jerdravee Morrison; Theresa L Parsons; Gerald H Friedland
Related Documents :
8841157 - Valsartan, a new angiotensin ii antagonist for the treatment of essential hypertension:...
387057 - A double-blind comparison of a novel indanone diuretic (mk-196) with hydrochlorothiazid...
24712167 - Pharmacokinetics of tramadol and its primary metabolite o-desmethyltramadol in african ...
17657617 - Enhancement of anti-inflammatory effects of calcium channel blockers by allopurinol and...
18320867 - Climacteric symptom control after the addition of low-dose esterified conjugated estrog...
40577 - Pipotiazine pharmacokinetics after p.o. and i.v. administration in man. correlation bet...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of drug and alcohol abuse     Volume:  39     ISSN:  1097-9891     ISO Abbreviation:  Am J Drug Alcohol Abuse     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7502510     Medline TA:  Am J Drug Alcohol Abuse     Country:  England    
Other Details:
Languages:  eng     Pagination:  80-5     Citation Subset:  IM    
Affiliation:
Yale University AIDS Program , New Haven, CT , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aripiprazole in an animal model of chronic alcohol consumption and dopamine D? receptor occupancy in...
Next Document:  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly ...